Clinical Pharmacology of Tisagenlecleucel in B-Cell Acute Lymphoblastic Leukemia.

CONCLUSIONS: Response to tisagenlecleucel was associated with increased expansion across a wide dose range. These results highlight the importance of cellular kinetics in understanding determinants of response to chimeric antigen receptor T-cell therapy.
PMID: 30190371 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - September 6, 2018 Category: Cancer & Oncology Authors: Mueller KT, Waldron ER, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August K, Hamilton J, Awasthi R, Stein AM, Sickert D, Chakraborty A, Levine BL, June CH, Tomassian L, Shah S, Leung M, Taran T, Wood PA, Maude SL Tags: Clin Cancer Res Source Type: research